Scope and Claims Review of US Patent 10,172,871 (GABAA Receptor Positive Modulation) and the U.S. Patent Landscape Impacted by It
US Patent 10,172,871 is drafted as a functional, formula-based method-of-treatment patent covering “positively modulating” GABAA receptors by administering a compound defined by a specific chemical formula, either as a bare compound or as a pharmaceutical composition with excipients. The claim set is broad on route of administration and treatment duration, with CNS-related disorders as the only disease limitation.
This document review maps claim scope, identifies the patent’s enforceable boundaries (what must be shown to infringe), and frames the likely U.S. patent-landscape exposure for generics and follow-on formulations targeting the same mechanism.
What is US Patent 10,172,871 and what do its claims actually cover?
Short answer: It covers (i) a method of positively modulating GABAA receptors in a subject by administering an effective amount of a “formula compound,” and (ii) the same method carried out with a pharmaceutical composition comprising that compound plus pharmaceutically acceptable excipients. Routes of administration include oral and injectable (IV, SC, IM), and chronic dosing is expressly covered. Disease is limited to “CNS-related disorder.”
Claim 1 (method, compound administration) defines infringement around “positive modulation” plus administering the formula compound
Claim 1: “A method for positively modulating a GABAA receptor in a subject … comprising administering … an effective amount of a compound of the formula [structure/formula]”
Key scope elements:
- Biological mechanism: “positively modulating” a GABAA receptor.
- Act of infringement: administering a compound to a subject.
- Dose concept: “effective amount” is functional and subject to expert interpretation.
- Chemical identity: the administered agent must be a compound of the formula (with the formula acting as the chemical gate).
What the claim does not require:
- No specific GABAA receptor subtype is recited.
- No specific CNS indication is recited beyond “CNS-related disorder.”
- No regimen schedule is required in claim 1 (chronic use appears in dependent claims).
Claim 2-6 (method, route and duration) expand route coverage and add chronic dosing
Claim 2: method of claim 1 where compound is administered orally, subcutaneously, intravenously, or intramuscularly.
Claim 3: method of claim 1 where compound is administered chronically.
Claim 4: method of claim 1 where subject has a CNS-related disorder.
Claim 5: claim 2 where orally administered.
Claim 6: claim 2 where intravenously administered.
Enforceable implications:
- The route is not narrowed in a way that would help a generic avoid infringement via delivery technique, because oral and multiple injectables are explicitly within scope.
- “Chronically” pulls in long-term dosing regimens and makes it harder to argue that short-course use falls outside the claim.
Claim 7 (method, pharmaceutical composition) covers formulation presence without changing mechanism
Claim 7: method for positively modulating a GABAA receptor comprising administering a pharmaceutical composition comprising:
- an effective amount of the formula compound, and
- a pharmaceutically acceptable excipient.
Scope:
- The claim is still a method claim, not a composition claim. But it makes excipients part of the infringing administered product.
- This can matter in litigation if an accused product is formulated versus administered as a pure compound preparation.
Claim 8-12 (composition method) extend route, chronic dosing, and CNS disorder for the composition case
Claim 8: method of claim 7 where composition is administered orally, SC, IV, or IM.
Claim 9: chronic administration.
Claim 10: subject has a CNS-related disorder.
Claim 11: claim 8 where oral.
Claim 12: claim 8 where intravenous.
Enforceable implications:
- For an accused product, it is enough that it is administered in one of the listed routes as a composition containing the formula compound and excipients. No specific excipient identity is required beyond “pharmaceutically acceptable.”
What parts of the claims are likely the hardest to prove in U.S. infringement?
In a method-of-use case, the plaintiff’s proof burden typically clusters into (i) chemistry, (ii) biological effect, and (iii) “administering in a subject” tied to the claimed patient condition and regimen.
1) “Compound of the formula” is the primary chemical infringement gate
The formula language is doing the heavy lifting. If an accused product’s active ingredient is outside the literal formula boundaries, infringement risk drops sharply unless doctrine-of-equivalents theories are available and factually supported.
What matters in claim construction:
- exact definition of substituents and ranges within the formula
- whether stereochemistry is required
- whether salts, solvates, prodrugs, or metabolites are included under the formula language (this depends on the specification and claim context)
2) “Positively modulating a GABAA receptor” is a functional biological outcome
Even if chemistry matches, the plaintiff must show that administration results in positive modulation at GABAA receptors. Positive modulation is typically established via pharmacology data:
- electrophysiology, cell-based assays, receptor binding/functional assays, or in vivo pharmacodynamic markers
For a defendant, this creates an evidentiary focus:
- whether the mechanism is truly positive modulation vs negative modulation vs allosteric effects not qualifying as “positive”
- whether the accused compound reaches sufficient exposure at the target receptor
3) The “CNS-related disorder” label is broad but not meaningless
“CNS-related disorder” can be construed broadly in practice, but it still requires tying the administration to a claimed patient population. In litigation, this becomes a nexus question:
- the accused product’s labeled indications, prescribing patterns, or trial inclusion criteria
4) “Chronically” is a regimen qualifier in dependent claims
Chronic dosing is explicitly claimed (claims 3 and 9). If a defendant markets only for acute use and avoids chronic dosing, that can narrow infringement of the dependent claims, while claim 1 and claim 7 without “chronic” may still remain.
How broad is the claim scope on route of administration, dosing duration, and patient population?
Route breadth is effectively “anything except what’s not listed”
Claims explicitly list: oral, subcutaneous, intravenous, intramuscular.
So typical avoidance strategies based on a different route are unlikely to work if the accused product uses one of these routes. If a party uses a route not listed (for example, intranasal) infringement might be argued off the face of the dependent claims, but independent claims 1 and 7 do not list routes, meaning route-specific design-arounds may not fully eliminate exposure.
Duration breadth is “chronically” for dependent claims, not required for independents
- Claims 1 and 7 do not require chronic dosing.
- Dependent claims 3 and 9 do.
So chronic regimen is a secondary scope boundary, not a primary one.
Disease scope is broad: “CNS-related disorder”
This is wider than a single indication and can cover multiple GABAergic or CNS conditions where GABAA positive modulation is relevant. That can widen labeling-based and off-label enforcement risk.
Does US 10,172,871 cover generics or only branded drug products?
It covers acts of administration, not just a commercial brand. If a generic product contains a compound that reads on the “formula compound,” and if it is used to positively modulate GABAA receptors in a CNS-related disorder population, the generic’s launch can create infringement exposure even if:
- the generic does not replicate the brand’s exact excipient package, provided it meets the composition definition in claim 7/8 (and/or uses a route that would still satisfy the broader independents)
Practical consequence for Paragraph IV and clearance strategy
For a generic applicant, two checks become critical:
- Chemical hit: does the ANDA active ingredient literally fall within the asserted formula?
- Use nexus: is the product used in a way that matches “positive modulation” in a “CNS-related disorder” with dosing/regimen aligning to the dependent claims at issue (especially chronic)?
What generic entry risks exist if a candidate uses the same mechanism (GABAA positive modulation) but a different chemical structure?
If a competitor uses a different scaffold that does not fall within the literal “formula compound,” infringement under claim 1/7 can fail. However:
- If the competitor’s structure is close, litigation often pivots to claim construction and doctrine-of-equivalents arguments.
- If the specification language supports broader genus interpretation (for example, if the “formula” is intended to cover a family and not a single narrow compound), then a “different but close” chemical may still be captured depending on how the formula is drafted.
On this record, the claims you provided do not include the actual formula, substituent variables, or stereochemical constraints, so the chemical boundary cannot be mapped precisely here. The key point remains: the formula is the central constraint. Mechanism alone (GABAA positive modulation) is not sufficient without the claimed chemical identity.
How does US 10,172,871 compare with typical GABAA modulators patent strategies?
This patent resembles common U.S. strategies for CNS small-molecule programs:
- Method-of-use claims tied to receptor modulation outcome.
- Composition method claims to reduce “formulation” escape routes.
- Route coverage across oral and multiple injectables.
- Disease category expressed as “CNS-related disorder” instead of a single indication, expanding infringement surface.
What is less common than very narrow disease claims:
- The use limitation is category-level, which can increase both enforcement reach and invalidity attack surface (category breadth vs enablement/possession, depending on specification support).
What is more common:
- Function-based biological effects (“positively modulating”) paired with a chemical definition.
What patent expiration and exclusivity timeline issues matter for U.S. freedom-to-operate?
A method patent’s enforceability ends upon patent expiration (and possible PTA/PTE adjustments). Your excerpt does not provide the issue date, filing date, priority claims, or listed regulatory exclusivities. Without those data, a precise expiration calendar cannot be produced in a way that would be reliable for litigation or investment timing.
What can be stated from the claim set:
- The patent is U.S. and contains method claims. If a competitor seeks entry before expiration, it typically must pursue one of:
- non-infringing design-around (chemical out of formula boundaries and/or use patterns)
- licensing
- invalidity/unenforceability defenses
- settlement with delayed entry
What is the Orange Book status of US 10,172,871 and how does it affect generic challenges?
Orange Book listings require mapping the patent to a specific marketed NDA/ANDA product and its listed active ingredient(s). The claim text alone does not identify:
- the active ingredient name
- the NDA/ANDA product
- the reference listed drug (RLD)
- the Orange Book publication(s) in which this patent is listed
Without that mapping, Orange Book status cannot be stated accurately, and Paragraph IV risk cannot be tied to a specific FDA listing record.
What formulation patents could be adjacent to 10,172,871 and create layered enforcement?
Even when a patent is method-of-use focused, enforcement in practice often overlaps with:
- polymorph/form patents (crystalline forms, amorphous, hydrates/solvates)
- salts and prodrugs (if included in the broader patent family)
- dosing regimen claims (titration, intervals, chronic maintenance)
- device-associated delivery (if applicable)
- manufacturing process patents (scale, purification, crystallization steps)
US 10,172,871 specifically includes a pharmaceutical composition method claim (claims 7-12). If the specification also discloses particular excipient types, dose forms, or formulation strategies, additional composition or formulation patents could exist in the same family, and those may be asserted alongside the method-of-use patent.
What patent litigation issues typically arise for receptor-modulation method claims like this?
In U.S. litigation, disputes commonly center on:
- claim construction of “positively modulating” (what assays/thresholds qualify)
- expert testimony on receptor modulation and pharmacodynamics
- construction and enablement arguments tied to the breadth of “CNS-related disorder”
- whether the asserted claims are obvious in view of prior art GABAA modulators with similar scaffolds
- whether the formula captures salts, stereoisomers, and analogs
Your excerpt provides claim language but not:
- the formula structure
- specification scope
- dependent claim numbering beyond 12
- any additional claim set
- listed defendants or case dockets
So litigation posture cannot be reconstructed beyond what the claim text suggests in general.
How many patents likely cover a GABAA positive modulator program with this claim style?
A method-of-use and composition method claim usually sits within a larger portfolio that may include:
- core compounds (composition-of-matter)
- process patents for making the compound
- additional method claims for CNS indications or subpopulations
- formulation patents for oral/injectable dose forms
This is a pattern-based assessment. The exact count for the specific program cannot be quantified from the claim excerpt alone because it depends on:
- the patent family size
- priority filings
- continuations and divisionals
- co-owned method-of-use continuations
Key Takeaways
- US Patent 10,172,871 is a method-of-use patent for positive modulation of GABAA receptors by administering a compound defined by a specific chemical formula.
- Claim 1/7 are the core independents; claims 2-6 and 8-12 broaden scope across oral and injectable routes and add dependent coverage for chronic administration and CNS-related disorders.
- In infringement analysis, the central contested elements are typically:
- whether the accused active ingredient falls within the formula
- whether dosing produces positive modulation of GABAA receptors
- whether use aligns with CNS-related disorder populations and, for dependent claims, chronic regimens.
- For generic or follow-on entrants, mechanism similarity alone is not sufficient. The patent is chemically gated by the formula compound and biologically tied to GABAA positive modulation.
- A reliable U.S. enforcement calendar (expiration date, PTA/PTE, and Orange Book listing mapping) cannot be produced from the claim language excerpt alone.
FAQs
1) What does “positively modulating a GABAA receptor” require for infringement?
It requires that administration of the claimed formula compound produces a positive modulatory effect at GABAA receptors, typically proven with pharmacology and receptor functional data.
2) Do claims 1 and 7 require oral dosing?
No. Routes are explicit in dependent claims (2-6 and 8-12). Claims 1 and 7 define administration without limiting route.
3) Can a defendant avoid claim 2 by using a route not listed (e.g., intranasal)?
Dependent claims 2 and 8 are route-limited, but route may still be covered under the broader independent claims 1 and 7 unless the claim construction limits “administering” to routes implied by the patent’s disclosures.
4) Is chronic dosing required to infringe the independent claims?
No. “Chronic” is added in dependent claims 3 and 9. Independent claims 1 and 7 do not recite “chronically.”
5) Does claim 7 capture any formulation with the compound and excipients?
It captures a pharmaceutical composition comprising an effective amount of the formula compound plus pharmaceutically acceptable excipients; it does not require a specific excipient identity in the claim text you provided.
References (APA)
- US Patent No. 10,172,871.
